• 1
    Goodwin RA, Asmis TR. Overview of systemic therapy for colorectal cancer. Clin Colon Rectal Surg 2009; 22: 2516.
  • 2
    Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003; 2: 4718.
  • 3
    Kim DW, Jo YS, Jung HS et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 2006; 91: 40706.
  • 4
    Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 32737.
  • 5
    Murray LJ, Abrams TJ, Long KR et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003; 20: 75766.
  • 6
    O'Farrell AM, Abrams TJ, Yuen HA et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101: 3597605.
  • 7
    Kodera Y, Katanasaka Y, Kitamura Y et al. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3. Breast Cancer Res 2011; 13: R66.
  • 8
    Pfizer Inc. SUTENT® (sunitinib) prescribing information. [Cited 4 Feb 2011.] Available from URL:
  • 9
    Raymond E, Dahan L, Raoul JL et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 50113.
  • 10
    Saltz LB, Rosen LS, Marshall JL et al. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol 2007; 25: 47939.
  • 11
    Starling N, Vázquez F, Cunningham D et al. A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. Ann Oncol 2011; 23: 11927.
  • 12
    Carrato A, Swieboda-Sadlej A, Staszewska-Skurczynska M et al. Final results from a randomized double-blind phase III study of sunitinib plus FOLFIRI vs. placebo plus FOLFIRI in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC) (abstract). Ann Oncol 2010; 21: O-0026.
  • 13
    Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 20516.
  • 14
    Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 22937.
  • 15
    Fuse N, Doi T, Ohtsu A et al. Safety of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) in Japan: a retrospective review of 48 patients with metastatic colorectal cancer. Int J Clin Oncol 2008; 13: 1449.
  • 16
    Okuyama Y, Hazama S, Nozawa H et al. Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1*28/*6 polymorphisms. Jpn J Clin Oncol 2011; 41: 47782.
  • 17
    Sunakawa Y, Ichikawa W, Fujita KI et al. UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer. Cancer Chemother Pharmacol 2011; 68: 27984.
  • 18
    Takahari D, Tsuji Y, Tanaka S et al. [Feasibility of modified FOLFIRI regimen for patients with refractory advanced or recurrent colorectal cancer]. Gan To Kagaku Ryoho 2007; 34: 20711.
  • 19
    Yukawa N, Yamamoto Y, Akaike M et al. [Modified FOLFIRI (l-LV, 5-fluorouracil and irinotecan) therapy for Japanese patients with metastatic colorectal cancer]. Gan To Kagaku Ryoho 2010; 37: 12915.
  • 20
    Sobrero A, Ackland S, Clarke S et al. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology 2009; 77: 1139.
  • 21
    Matsumoto R, Kuroda T, Yamada H, Hasegawa K, Mamiya Y, Kon A. [Chemotherapy with bevacizumab (BV) + modified FOLFOX6 for unresectable colorectal cancer]. Gan To Kagaku Ryoho 2009; 36: 22079.
  • 22
    Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 2010; 66: 35771.
  • 23
    Hamaguchi T, Yoshino T, Ohtsu A et al. Phase I study of first-line sunitinib plus modified FOLFOX6 (mFOLFOX6) in Japanese patients with metastatic colorectal cancer. ECCO 15–34th ESMO Multidisciplinary Congress, September 20–24, 2009 (Abstract 6063).
  • 24
    Ishida H, Fujita KI, Akiyama Y et al. Regimen selection for first-line FOLFIRI and FOLFOX based on UGT1A1 genotype and physical background is feasible in Japanese patients with advanced colorectal cancer. Jpn J Clin Oncol 2011; 41: 61723.